相关实验视频
Updated: Jun 16, 2025
16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.2K
[心力衰竭住院后指导导向医疗疗的快速升级]
G Tamás Gergely1, Fanni Bánfi-Bacsárdi1, Anna Komáromi1
11 Gottsegen György Országos Kardiovaszkuláris Intézet, Felnőtt Kardiológiai Osztály Budapest, Haller u. 29., 1096 Magyarország.
Orvosi hetilap
|August 15, 2024
概括
在心力衰竭住院治疗后,以指导方针为导向的医疗治疗的快速升级是可行的和安全的. 这种方法实现了高剂量的四倍疗法,提高了患者的满意度和安全.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭管理的管理
- 药物治疗 药物治疗
背景情况:
- 欧洲心脏病学会的指导方针建议在心力衰竭后住院治疗的指导方针医疗疗 (GDMT) 快速升级.
- STRONG-HF试验支持这一建议,但其严格的随机化标准限制了现实世界的可行性数据.
- 目前的临床实践缺乏关于在心力衰竭住院后快速GDMT升位的实际应用的数据.
研究的目的:
- 评估快速GDMT升位在心力衰竭中可行性和安全性,以减少喷射率 (HFrEF) 患者住院后.
- 在现实临床环境中评估四倍治疗的目标剂量达到的程度.
- 为了收集患者对快速升级定位过程的反.
主要方法:
- 对9名连续入院到心力衰竭病房的HFrEF患者进行了回顾性试点研究.
- 患者在出院后六周内在门诊诊所接受了快速GDMT升标.
- 资格标准与STRONG-HF试验相似:静脉血压≥100 mmHg,心率≥60/分钟,≤5 mmol/L,eGFR≥30 mL/分钟/1.73 m2.
主要成果:
- 在出院时,九名患者中有八名开始接受四重疗法.
- 在快速升位后,达到高目标剂量:氨酸-动脉素系统抑制剂 (RASi) 94%,βB抑制剂 (βB) 93%,矿物质皮质醇受体对抗剂 (MRA) 100%和-葡萄糖共载体2抑制剂 (SGLT2i).
- 没有报告严重的不良事件;三名患者的低血压/胸心限制GDMT. 患者报告说,他们的满意度和安全性有所提高.
结论:
- 在心力衰竭住院后快速增加GDMT标配在现实世界中是可行的和安全的.
- 高剂量四倍疗法是可以实现的,尽管需要密集的临床医生和患者的努力.
- 该过程提高了患者的满意度和安全感,而不会增加负担.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:26Heart Failure Drugs: Inotropic Agents
547
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
547
01:22Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K